Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Cognition Therapeutics ( (CGTX) ) has issued an announcement.
Cognition Therapeutics announced promising results from their Phase 2 SHIMMER study, which highlighted the efficacy and safety of their lead product, zervimesine, in treating dementia with Lewy bodies (DLB). The study showed strong responses across behavioral, functional, cognitive, and movement measures, positioning zervimesine as a potential first-to-market treatment for DLB, further supported by robust intellectual property and a favorable safety profile.
More about Cognition Therapeutics
Cognition Therapeutics Inc. operates in the biotechnology industry, focusing on the development of innovative treatments for neurodegenerative diseases. Their primary product candidates include zervimesine, targeting conditions like Alzheimer’s disease and dementia with Lewy bodies.
YTD Price Performance: 5.56%
Average Trading Volume: 7,563,266
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $31.61M
For an in-depth examination of CGTX stock, go to TipRanks’ Stock Analysis page.
